MorphoSys AG (MOR)

NASDAQ: MOR · IEX Real-Time Price · USD
6.03
-0.11 (-1.79%)
Aug 16, 2022 11:04 AM EDT - Market open
-1.79%
Market Cap 828.40M
Revenue (ttm) 173.89M
Net Income (ttm) -595.50M
Shares Out 137.38M
EPS (ttm) -4.61
PE Ratio n/a
Forward PE 322.58
Dividend n/a
Ex-Dividend Date n/a
Volume 15,860
Open 6.14
Previous Close 6.14
Day's Range 5.96 - 6.15
52-Week Range 4.35 - 15.16
Beta 0.92
Analysts Buy
Price Target 9.89 (+64.0%)
Earnings Date Aug 3, 2022

About MOR

MorphoSys AG, a commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic antibodies for patients suffering from cancer and autoimmune diseases in the United States. It offers Tafasitamab, an antibody for the treatment of B cell malignancies, including diffuse large B-cell lymphoma, follicular lymphoma, and marginal zone lymphoma. The company also develops Pelabresib, a small molecule that is in Phase II clinical trial to treat myelofibrosis; Felzartamab, an antibody directed against... [Read more...]

Industry Biotechnology
IPO Date Mar 9, 1999
CEO Jean-Paul Kress
Employees 648
Stock Exchange NASDAQ
Ticker Symbol MOR
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 18 analysts, the average rating for MOR stock is "Buy." The 12-month stock price forecast is 9.89, which is an increase of 64.01% from the latest price.

Price Target
$9.89
(64.01% upside)
Analyst Consensus: Buy
Stock Forecasts

News

MorphoSys AG Reports Second Quarter and First Half 2022 Financial Results

PLANEGG/MUNICH, Germany--(BUSINESS WIRE)--Conference call and webcast (in English) tomorrow, August 4, 2022, at 2:00pm CEST (1pm BST/8:00am EDT) MorphoSys AG (FSE: MOR; NASDAQ: MOR) reports results for ...

MorphoSys AG: Invitation to MorphoSys' Second Quarter and First Half Year 2022 Results Conference Call on August 4 , ...

Conference Call Alert PLANEGG and MUNICH, GERMANY / ACCESSWIRE / July 28, 2022 / MorphoSys AG (FSE:MOR); (NASDAQ:MOR) will publish its results for the second quarter and first half year 2022 results on ...

MorphoSys Reports Preliminary Q2 2022 Monjuvi U.S. Sales and Updates Financial Guidance for 2022

Preliminary Q2 2022 Monjuvi U.S. net product sales of US$ 23.3 million (€ 21.7 million) Update of financial guidance range for 2022 Monjuvi U.S. net product sales (now US$ 90 to US$ 110 million) Update ...

MorphoSys AG Reports Preliminary Q2 2022 Monjuvi U.S. Sales and Updates Financial Guidance for 2022

Publication of an inside information according to Article 17 para. 1 of the Regulation (EU) No.

I-Mab Partner MorphoSys Announces New License Agreements for Felzartamab and TJ210

SHANGHAI and GAITHERSBURG, Md. , June 15, 2022 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercializa...

Other symbols: IMAB

MorphoSys Stock Skyrockets On Entering Equity Participation and License Agreements With HIBio

MorphoSys AG (NASDAQ: MOR) and Human Immunology Biosciences, Inc. (HIBio), a biotechnology company, have established an equity participation agreement and license agreements to allow HIBio to develop an...

MorphoSys and HIBio Enter Into Equity Participation and License Agreements for Felzartamab and MOR210

PLANEGG/MUNICH, Germany & SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--MorphoSys AG (FSE: MOR; NASDAQ: MOR) and Human Immunology Biosciences, Inc. (HIBio), a South San Francisco-based biotechnology com...

MorphoSys (MOR) Gains on Oncology Collaboration With Pfizer

MorphoSys (MOR) and Pfizer collaborate to develop a combination of MOR's Monjuvi and Pfizer's checkpoint inhibitor candidate, TTI-622, for treating r/r DLBCL.

Pfizer, MorphoSys and Incyte Enter into Clinical Trial Collaboration for Monjuvi® (tafasitamab-cxix) in Combination w...

NEW YORK & BOSTON & WILMINGTON, Del.--(BUSINESS WIRE)--Pfizer Inc. (NASDAQ:PFE), MorphoSys U.S. Inc., a fully owned subsidiary of MorphoSys AG (FSE: MOR; NASDAQ:MOR), and Incyte (NASDAQ:INCY) today anno...

Other symbols: INCYPFE

MorphoSys Presents Multiple Analyses of the MANIFEST Phase 2 Trial Investigating the Potential of Pelabresib in the T...

MUNICH--(BUSINESS WIRE)--MorphoSys AG (FSE: MOR; NASDAQ: MOR) is presenting data from multiple analyses of the ongoing MANIFEST study, an open-label Phase 2 clinical trial of pelabresib, an investigatio...

MorphoSys AG Reports Outcome of Annual General Meeting 2022

PLANEGG/MUNICH, GERMANY / ACCESSWIRE / May 18, 2022 / MorphoSys AG (FSE:MOR); (NASDAQ:MOR) announced today that its shareholders approved all resolutions proposed by the Company´s Management and Supervi...

MorphoSys to Present New Data on Pelabresib and Monjuvi® (tafasitamab-cxix) at the 2022 European Hematology Associati...

BOSTON--(BUSINESS WIRE)--MorphoSys AG (FSE: MOR; NASDAQ: MOR) announced that new data on pelabresib and tafasitamab, marketed in the U.S. as Monjuvi® and in Europe as Minjuvi®, will be presented during ...

MorphoSys AG Reports First Quarter 2022 Financial Results

PLANEGG/MUNICH, Germany--(BUSINESS WIRE)--MorphoSys AG (FSE: MOR; NASDAQ: MOR) reports results for the first quarter 2022.

Invitation to MorphoSys' First Quarter 2022 Financial Results Conference Call on May 5, 2022

PLANEGG/MUNICH, GERMANY / ACCESSWIRE / April 28, 2022 / MorphoSys AG (FSE:MOR)(NASDAQ:MOR) will publish its results for the first quarter 2022 on May 4, 2022 at 10:00 pm CEST (9:00 pm GMT; 4:00 pm EDT)....

Wall Street Analysts Believe MorphoSys AG Unsponsored ADR (MOR) Could Rally 213%: Here's is How to Trade

The mean of analysts' price targets for MorphoSys AG Unsponsored ADR (MOR) points to a 213.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agree...

MorphoSys and Incyte Announce Swissmedic Temporary Approval of Minjuvi(R) (tafasitamab) in Combination with Lenalidom...

MorphoSys and Incyte Announce Swissmedic Temporary Approval of Minjuvi(R) (tafasitamab) in Combination with Lenalidomide for the Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymp...

MorphoSys AG Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update

PLANEGG/MUNICH, Germany--(BUSINESS WIRE)--MorphoSys AG (FSE: MOR; NASDAQ: MOR) reports results for the fourth quarter and full year 2021. "In 2021, we accelerated our vision to become a leader in hemato...

National Comprehensive Cancer Network(R) Updates Designation of Monjuvi(R) (tafasitamab-cxix) to Preferred Regimen in...

BOSTON, MA / ACCESSWIRE / March 15, 2022 / MorphoSys U.S. Inc., a fully owned subsidiary of MorphoSys AG (FSE:MOR)(NASDAQ:MOR), announced today that the National Comprehensive Cancer Network(R) (NCCN) C...

Invitation to MorphoSys' Full Year Results 2021 Conference Call on March 17, 2022

Conference Call Alert PLANEGG and MUNICH, GERMANY / ACCESSWIRE / March 10, 2022 / MorphoSys AG (FSE:MOR);(NASDAQ:MOR) will publish its results for the financial year 2021 on March 16, 2022 at 9:00 pm CE...

MorphoSys AG Reports Non-Cash Impairment Charge of € 231 Million on Goodwill After Consolidation of Research and Disc...

Publication of an inside information according to Article 17 para. 1 of the Regulation (EU) No 596/2014 PLANEGG and MUNICH, GERMANY / ACCESSWIRE / March 10, 2022 / MorphoSys AG (FSE:MOR) (NASDAQ:MOR) an...

MorphoSys Reports Preliminary 2021 Monjuvi U.S. Sales and Provides 2022 Financial Guidance

Preliminary 2021 Monjuvi U.S. net product sales of US$ 79.1 million ( € 66.9 million) Anticipated 2022 Monjuvi U.S. net product sales in the range of US$ 110 to 135 million PLANEGG / MUNICH, GERMANY / A...

MorphoSys To Present At the 40th Annual J.P. Morgan Healthcare Conference

PLANEGG / MUNICH, GERMANY / ACCESSWIRE / Janauary 10, 2022 / MorphoSys AG (FSE:MOR; NASDAQ:MOR), announced today that Jean-Paul Kress, M.D., Chief Executive Officer of MorphoSys, will present at the 40 ...

MorphoSys Presents Latest Data from the Phase 2 MANIFEST Study Evaluating the Potential of Pelabresib in the Treatmen...

MorphoSys presents latest data from the Phase 2 MANIFEST Study evaluating the potential of pelabresib in the treatment of myelofibrosis Data presented during poster and oral sessions at the 63rd America...

MorphoSys and Incyte Announce Additional Real-World Evidence Results from RE-MIND2 Study of Tafasitamab (Monjuvi(R)) ...

- RE-MIND2 compared patient outcomes from pivotal L-MIND study with matched patient populations treated with NCCN/ESMO recommended therapies - Results from the retrospective cohort analysis indicate sig...

Other symbols: INCY

MorphoSys and Incyte Announce Additional Real-World Evidence Results from RE-MIND2 Study of Tafasitamab (Monjuvi®) in...

BOSTON & WILMINGTON, Del.--(BUSINESS WIRE)--MorphoSys US Inc., a fully owned subsidiary of MorphoSys AG (FSE: MOR; NASDAQ: MOR), and Incyte (NASDAQ:INCY) today announced additional real-world evidence r...

Other symbols: INCY